The race to lead the next era of medicine is accelerating. Global competitors are rapidly expanding their biotech capabilities while AI is reshaping how new therapies are developed and pushing the boundaries of what's possible. As geopolitical competition intensifies, the challenge is ensuring the U.S. remains the global leader in biotechnology while creating a policy environment that supports innovation and brings new treatments to patients.
In 1976, Genentech launched the biotechnology industry. Today, that same spirit of disruption drives us to chart the course for the next half-century.
Subscribe to Axios Future of Health Care: Health Care policy and business analysis from Caitlin Owens and Adriel Bettelheim.